Interpace Biosciences (IDXG) Stock Price, News & Analysis

Company Overview

Interpace Biosciences, Inc. is a molecular diagnostics company focused on providing testing and pathology services that support the diagnosis and management of cancer and other complex diseases. The company’s tests are designed to help physicians assess disease risk, improve diagnostic confidence and guide treatment decisions.

Its portfolio has included molecular tests for thyroid nodules, pancreatic cysts and gastrointestinal conditions. Key offerings include ThyGeNEXT and ThyraMIR for evaluating thyroid nodules, as well as PancraGEN and PanDNA for assessing pancreatic cysts. These products combine molecular analysis with clinical and pathology information to help distinguish potentially serious disease from conditions that may be monitored more conservatively.

Interpace serves physicians, hospitals, laboratories and other health-care providers primarily in the United States through its laboratory and commercial operations. The company previously operated under the PDI name before adopting the Interpace Biosciences identity as its business became centered on molecular diagnostics and personalized medicine.

Key Stats

• Today's Range: $6.42 to $6.42
• 50-Day Range: $1.42 to $6.41
• 52-Week Range: $6.01 to $6.43
• Volume: 313 shs
• Average Volume: 3,545 shs
• Market Capitalization: $35.57 million
• P/E Ratio: 80.25
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Interpace Biosciences Stock Analysis - MarketRank™

Interpace Biosciences scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Interpace Biosciences.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Interpace Biosciences is 80.25, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.82.

Price to Earnings Ratio vs. Sector

The P/E ratio of Interpace Biosciences is 80.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.05.

Price to Book Value per Share Ratio

Interpace Biosciences has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Interpace Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Interpace Biosciences has a short interest ratio ("days to cover") of 0.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Interpace Biosciences has recently decreased by 80.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Interpace Biosciences does not currently pay a dividend.

Dividend Growth

Interpace Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.38

News Sentiment

Interpace Biosciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Interpace Biosciences this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Interpace Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.93% of the stock of Interpace Biosciences is held by insiders.

Percentage Held by Institutions

5.73% of the stock of Interpace Biosciences is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: OTCMKTS:IDXG
• CIK: 1054102
• Web: www.interpace.com
• Phone: 855-776-6419
• Fax: 862-207-7820
• Employees: 152
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.08
• Trailing P/E Ratio: 80.25
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $24.58 million
• Net Margins: 67.64%
• Pretax Margin: 11.06%
• Return on Equity: 145.40%
• Return on Assets: 87.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.22
• Quick Ratio: 2.22

Sales & Book Value

• Annual Sales: $38.73 million
• Price / Sales: 0.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $25.25 per share
• Price / Book: 0.25

Miscellaneous

• Outstanding Shares: 5,540,000
• Free Float: 5,490,000
• Market Cap: $35.57 million
• Optionable: Not Optionable
• Beta: 0.61